India has developed 'Covaxin', the first COVID-19 vaccine by Bharat Biotech Company, Hyderabad which is announced on Monday and is ready for human clinical trials.
The vaccine has been approved by the Drug Controller General of India (DCGI) and the first vaccine that has got approval of the drug controller for phase 1 and II human clinical trials.
COVAXIN is an inactivated vaccine, created from a strain of the infectious SARS-CoV-2 virus, that has shown promise in preclinical studies, demonstrating extensive safety and effective immune responses.
The DCGI gave the permission to the company to initiate phase I & II human clinical trials after it submitted results generated from preclinical studies, demonstrating safety and immune response. According to the company, the human clinical trial will start from July.
Health officials and various scientists around the world are racing to develop a vaccine against the novel coronavirus but has not found appropriate result.